This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Elledge, R. M. Articles by Allred, D. C. Search for Related Content PubMed PubMed Citation Articles by Elledge, R. M. Articles by Allred, D. C.

p53 Protein Accumulation Detected by Five Different Antibodies: Relationship to Prognosis and Heat Shock Protein 70 in Breast Cancer¹

University of Texas Health Science Center, Division of Medical Oncology [R. M. E., G. M. C., S. A. W. F., Y-Y. Y.], and the Department of Pathology [D. C. A.], 7703 Floyd Curl Drive, San Antonio, Texas 78284-7884

Nuclear accumulation of p53 protein is associated with a poorer clinical outcome in breast cancer patients. Heat shock protein 70 (hsp70) is a chaperone that binds to mutant p53 and consequently could regulate its accumulation or localization. The aims of this study were to determine if the prognostic significance of p53 accumulation was dependent on the type of antibody used for detection and whether hsp70 was associated with this accumulation. Node-negative breast tumors (n = 169) were examined by immunohistochemistry for nuclear p53, cytoplasmic or nuclear hsp70, and for p53 gene alteration by single-strand conformation polymorphism analysis. Frozen sections of pulverized breast tumors were stained with five p53 antibodies (240, 1801, 421, BP53-12, and CM1), a cocktail of both 240 and 1801, and the hsp70 antibody C92. Protein level was expressed as the sum of a proportion and intensity score (total 0, 2–8) with 2 defined as positive staining. The cocktail 240/1801 gave the highest rate of positive staining (45%), followed by BP53-12 (35%), 1801 (27%), 240 (25%), CMI (24%), and 421 (18%), with a high correlation between antibodies. Positive staining with each individual antibody or the cocktail was significantly associated with estrogen receptor and progesterone receptor negativity, age < 50, and high S-phase fraction. Only staining detected by the 240/1801 cocktail was associated with significantly worse overall survival; 85 versus 70% at 5 years for p53-negative compared to p53-positive tumors, respectively (P = 0.02). There was no association between nuclear or cytoplasmic hsp70 staining and accumulation of p53. Patients that were p53-negative/cytoplasmic hsp70-positive had a better overall survival than those that were p53-negative/cytoplasmic hsp70-negative. No other combination of p53 and hsp70 status could further define subsets of patients with a significantly different prognosis compared to p53 status alone. Tumors without a detectable p53 gene alteration by single-strand conformation polymorphism but with accumulated p53 protein did not have relatively increased levels of hsp70. We conclude that in node-negative breast cancer, the cocktail of two antibodies, 240/1801, resulted in the highest rate of positive staining and was most strongly associated with overall survival compared with either antibody alone or with the other individual antibodies. By immunohistochemistry, nuclear accumulation of p53 was not associated with cytoplasmic or nuclear hsp70 levels.

¹ This work was supported by the Medical Oncology Program Project, NIH CA 30195, The San Antonio Cancer Institute, NIH P30-CA 54174, and the Specialized Program of Research Excellence, NIH P50-CA 58183-02. R. M. E. is the recipient of a SPORE Career Development Award.

² To whom requests for reprints should be addressed, at Department of Pathology, University of Texas Health Science Center, 7703 Floyd Curl Dr., San Antonio, TX 78284-7750.

Received 1/26/94. Accepted 5/16/94.

This article has been cited by other articles:

				M. E. Couch, R. L. Ferris, J. A. Brennan, W. M. Koch, E. M. Jaffee, M. S. Leibowitz, G. T. Nepom, H. A. Erlich, and D. Sidransky Alteration of Cellular and Humoral Immunity by Mutant p53 Protein and Processed Mutant Peptide in Head and Neck Cancer Clin. Cancer Res., December 1, 2007; 13(23): 7199 - 7206. [Abstract] [Full Text] [PDF]

				R. L. Ferris and J. R. Grandis NF-{kappa}B Gene Signatures and p53 Mutations in Head and Neck Squamous Cell Carcinoma Clin. Cancer Res., October 1, 2007; 13(19): 5663 - 5664. [Full Text] [PDF]

				S.-S. Ko, Y.-S. Na, C.-S. Yoon, J.-Y. Park, H.-S. Kim, M.-H. Hur, H.-K. Lee, Y.-K. Chun, S.-S. Kang, B.-W. Park, et al. The Significance of c-erbB-2 Overexpression and p53 Expression in Patients With Axillary Lymph Node--Negative Breast Cancer: A Tissue Microarray Study International Journal of Surgical Pathology, April 1, 2007; 15(2): 98 - 109. [Abstract] [PDF]

				Y. Sumiyoshi, Y. Kakeji, A. Egashira, K. Mizokami, H. Orita, and Y. Maehara Overexpression of Hypoxia-Inducible Factor 1{alpha} and p53 Is a Marker for an Unfavorable Prognosis in Gastric Cancer Clin. Cancer Res., September 1, 2006; 12(17): 5112 - 5117. [Abstract] [Full Text] [PDF]

				A. E. Hershey, R. R. Dubielzig, M. L. Padilla, and S. C. Helfand Aberrant p53 Expression in Feline Vaccine-associated Sarcomas and Correlation with Prognosis Vet. Pathol., November 1, 2005; 42(6): 805 - 811. [Abstract] [Full Text] [PDF]

				C. J. Fabian, B. F. Kimler, C. M. Zalles, J. R. Klemp, S. Kamel, S. Zeiger, and M. S. Mayo Short-Term Breast Cancer Prediction by Random Periareolar Fine-Needle Aspiration Cytology and the Gail Risk Model J Natl Cancer Inst, August 2, 2000; 92(15): 1217 - 1227. [Abstract] [Full Text] [PDF]

				D. I. Quinn, S. M. Henshall, D. R. Head, D. Golovsky, J. D. Wilson, P. C. Brenner, J. J. Turner, W. Delprado, J. F. Finlayson, P. D. Stricker, et al. Prognostic Significance of p53 Nuclear Accumulation in Localized Prostate Cancer Treated with Radical Prostatectomy Cancer Res., March 1, 2000; 60(6): 1585 - 1594. [Abstract] [Full Text]

				H. LaRue, P. Allard, M. Simoneau, C. Normand, C. Pfister, L. Moore, F. Meyer, B. Tetu, and Y. Fradet P53 point mutations in initial superficial bladder cancer occur only in tumors from current or recent cigarette smokers Carcinogenesis, January 1, 2000; 21(1): 101 - 106. [Abstract] [Full Text] [PDF]

				C. A. Smith, A. A. Pollice, L.-P. Gu, K. A. Brown, S. G. Singh, L. E. Janocko, R. Johnson, T. Julian, D. Hyams, N. Wolmark, et al. Correlations Among p53, Her-2/neu, and ras Overexpression and Aneuploidy by Multiparameter Flow Cytometry in Human Breast Cancer: Evidence for a Common Phenotypic Evolutionary Pattern in Infiltrating Ductal Carcinomas Clin. Cancer Res., January 1, 2000; 6(1): 112 - 126. [Abstract] [Full Text]

				M. R. Posner, P. G. Johnston, R. B. Tishler, J. Andersen, M. Fiorentino, P. M. Busse, L. A. Cavacini, A. D. Colevas, J. Clark, and C. M. Norris The Prognostic Value of Thymidylate Synthase and p53 Expression in Patients Treated with Induction Chemotherapy for Squamous Cell Carcinoma of the Head and Neck Oncologist, December 1, 1998; 3(6): 424 - 431. [Abstract] [Full Text]

				P. Robbins p53 and Breast Cancer International Journal of Surgical Pathology, October 1, 1996; 4(2): 93 - 110. [Abstract] [PDF]